{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "15383157",
  "DateCompleted": {
    "Year": "2005",
    "Month": "06",
    "Day": "13"
  },
  "DateRevised": {
    "Year": "2016",
    "Month": "10",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2004",
        "Month": "09",
        "Day": "22"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1461-1457",
      "JournalIssue": {
        "Volume": "8",
        "Issue": "1",
        "PubDate": {
          "Year": "2005",
          "Month": "Mar"
        }
      },
      "Title": "The international journal of neuropsychopharmacology",
      "ISOAbbreviation": "Int J Neuropsychopharmacol"
    },
    "ArticleTitle": "Effect of intraperitoneal acetyl-L-carnitine (ALCAR) on anxiety-like behaviours in rats.",
    "Pagination": {
      "StartPage": "65",
      "EndPage": "74",
      "MedlinePgn": "65-74"
    },
    "Abstract": {
      "AbstractText": [
        "Acetyl-L-carnitine (ALCAR) is an acetyl derivative of carnitine, an endogenous molecule synthesized in vivo and supplemented by diet (mainly via meat and dairy products). Several parallel, double-blind, placebo-controlled studies have demonstrated that ALCAR treatment produces beneficial effects in geriatric depression. Since most antidepressants also have anti-anxiety effects we examined whether ALCAR shows anti-anxiety effects in a rat model of anxiety. Compared to a saline-injected control group, chronic administration of ALCAR at doses of 10 and 100 mg/kg (tested 24 h after the last dose administration) showed no effects, whereas doses of 50 and 75 mg/kg significantly reduced anxiety-like behaviours in the elevated plus-maze. Acute ALCAR (100 mg/kg), on the other hand (tested 6 h after administration), demonstrated anxiogenic effects. Our data suggest that chronic ALCAR administration may produce an inverted U-shaped curve of dose-dependent changes in anxiety-like behaviour. The precise mechanism by which ALCAR decreases anxiety-like behaviour after peripheral administration remains to be determined."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel."
          }
        ],
        "LastName": "Levine",
        "ForeName": "Joseph",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kaplan",
        "ForeName": "Zeev",
        "Initials": "Z"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Pettegrew",
        "ForeName": "Jay W",
        "Initials": "JW"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "McClure",
        "ForeName": "Richard J",
        "Initials": "RJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gershon",
        "ForeName": "Samuel",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Buriakovsky",
        "ForeName": "Igor",
        "Initials": "I"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cohen",
        "ForeName": "Hagit",
        "Initials": "H"
      }
    ],
    "PublicationTypeList": [
      "Comparative Study",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Int J Neuropsychopharmacol",
    "NlmUniqueID": "9815893",
    "ISSNLinking": "1461-1457"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Anxiety Agents"
    },
    {
      "RegistryNumber": "6DH1W9VH8Q",
      "NameOfSubstance": "Acetylcarnitine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "pharmacology",
        "toxicity"
      ],
      "DescriptorName": "Acetylcarnitine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Anxiety Agents"
    },
    {
      "QualifierName": [
        "chemically induced",
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Arousal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Models, Animal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Dose-Response Relationship, Drug"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Administration Schedule"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Evaluation, Preclinical"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Exploratory Behavior"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Fear"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Maze Learning"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats, Sprague-Dawley"
    }
  ]
}